Fig. 1

MiR-34c is under-expressed in NPC and downregulated by TGFβ1. a Relative miR-34c expression in normal patients (not diagnosed with NPC) vs. NPC patients (using data from Bruce et al., 2014 [11]). b Relative expression (qRT-PCR) of miR-34c in NP69, NP460, and C666–1 cell lines, normalized to NP69 cells. c Whole cell lysate (WCL) Western blotting (WB) of NP69, C666–1, and NP460 cells using anti-TGFβ1 antibody (αTGFβ1), with anti-β-actin (αβ-actin) as the loading control. Full-length blots are presented in Additional file 5: Figure S5. (D and E) Relative miR-34c expression assessed by qRT-PCR after treatment with 10 ng/mL of recombinant TGFβ1 in NP69 (d) and NP460 (e) cells. UT = untreated. f WB performed on WCL of stably transfected NP69-miR-control, NP69-anti-miR-34c, and NP69-pre-miR-449b cells using anti-TGFβ1 antibody, with anti-β-actin (αβ-actin) as the loading control (top); corresponding relative miR-34c expression assessed by qRT-PCR (bottom). Full-length blots are presented in Additional file 5: Figure S5. The data are represented as the mean ± SEM of at least three independent experiments. *** P < 0.001